BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34272660)

  • 21. Dose volume analysis of radiotherapy for inoperable patients with stage I-II endometrial carcinoma.
    Ohkubo Y; Kato S; Kiyohara H; Tsuruoka I; Tamaki T; Noda SE; Ohno T; Nakano T
    J Radiat Res; 2011; 52(5):666-73. PubMed ID: 21857147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer.
    Assenholt MS; Vestergaard A; Kallehauge JF; Mohamed S; Nielsen SK; Petersen JB; Fokdal L; Lindegaard JC; Tanderup K
    Brachytherapy; 2014; 13(4):361-8. PubMed ID: 24656732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant electronic brachytherapy for endometrial carcinoma: A 4-year outcomes report.
    Sarria GR; Sperk E; Wenz F; Schneider F; Abo-Madyan Y; Giordano FA; Ehmann M
    Brachytherapy; 2020; 19(5):635-641. PubMed ID: 32651094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?
    Carpenter DJ; Stephens SJ; Ayala-Peacock DN; Shenker RF; Raffi J; Meltsner SG; Craciunescu O; Chino JP
    Brachytherapy; 2023; 22(2):181-187. PubMed ID: 36335036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and outcomes associated with high-dose rate brachytherapy for medically inoperable endometrial cancer.
    Yaney A; Healy E; Wald P; Olsen M; Pan X; Martin D; Quick A
    Brachytherapy; 2021; 20(2):368-375. PubMed ID: 33353844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes using image-guided interstitial brachytherapy for definitive cervical cancer patients with high-risk clinical target volumes greater than 30 cc.
    Wang C; Raince J; Swamy U; Park SJ; Zaide L; Mesko S; Demanes DJ; Kamrava M
    Brachytherapy; 2018; 17(2):392-398. PubMed ID: 29128230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The results of primary HDR-afterloading brachytherapy in corpus carcinoma].
    Knocke TH; Kucera H; Weidinger B; Höller W; Pötter R
    Strahlenther Onkol; 1995 Apr; 171(4):195-201. PubMed ID: 7740406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
    Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.
    Pötter R; Haie-Meder C; Van Limbergen E; Barillot I; De Brabandere M; Dimopoulos J; Dumas I; Erickson B; Lang S; Nulens A; Petrow P; Rownd J; Kirisits C;
    Radiother Oncol; 2006 Jan; 78(1):67-77. PubMed ID: 16403584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MRI based 3D brachytherapy planning of the cervical cancer -  our experiences with the use of the uterovaginal Vienna Ring MR CT applicator].
    Vojtíšek R; Mouryc F; Cechová D; Ciprová R; Ferda J; Fínek J
    Klin Onkol; 2014; 27(1):45-51. PubMed ID: 24635437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results.
    Coon D; Beriwal S; Heron DE; Kelley JL; Edwards RP; Sukumvanich P; Zorn KK; Krivak TC
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):779-83. PubMed ID: 18258388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.
    Acharya S; Perkins SM; DeWees T; Fischer-Valuck BW; Mutch DG; Powell MA; Schwarz JK; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):649-57. PubMed ID: 26461007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of morbidity after external radiotherapy and intracavitary brachytherapy in 771 patients with carcinoma of the uterine cervix or endometrium.
    Yalman D; Arican A; Ozsaran Z; Celik OK; Yürüt V; Esassolak M; Haydaroglu A
    Eur J Gynaecol Oncol; 2002; 23(1):58-62. PubMed ID: 11876395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
    Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
    Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interfractional change of high-risk CTV D90 during image-guided brachytherapy for uterine cervical cancer.
    Ohkubo Y; Ohno T; Noda SE; Kubo N; Nakagawa A; Kawahara M; Abe T; Kiyohara H; Wakatsuki M; Nakano T
    J Radiat Res; 2013 Nov; 54(6):1138-45. PubMed ID: 23732770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External-beam radiotherapy and/or HDR brachytherapy in postoperative endometrial cancer patients: clinical outcomes and toxicity rates.
    De Sanctis V; Agolli L; Valeriani M; Narici S; Osti MF; Patacchiola F; Mossa B; Moscarini M; Maurizi Enrici R
    Radiol Med; 2013 Mar; 118(2):311-22. PubMed ID: 22580814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience.
    Perrucci E; Lancellotta V; Bini V; Zucchetti C; Mariucci C; Montesi G; Saccia S; Palumbo I; Aristei C
    Brachytherapy; 2016; 15(2):177-84. PubMed ID: 26727332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computed tomography-based image-guided brachytherapy for cervical cancer: correlations between dose-volume parameters and clinical outcomes.
    Kusada T; Toita T; Ariga T; Maemoto H; Hashimoto S; Shiina H; Kakinohana Y; Heianna J; Nagai Y; Kudaka W; Aoki Y; Murayama S
    J Radiat Res; 2018 Jan; 59(1):67-76. PubMed ID: 29186565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.